Anew Therapeutics Pte Ltd. has synthesized heterocyclic compounds acting as interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction inhibitors. As such, they are reported to be useful for the treatment of Crohn’s disease, type 1 diabetes, dry eye, multiple sclerosis, myositis, psoriasis, rheumatoid arthritis and vitiligo, among others.